KTTA•benzinga•
Pasithea Therapeutics Announced That The External Safety Review Committee Recommended Proceeding Phase 1 Trial Of PAS-004 In Advanced Cancer To Cohort 4, 15mg Capsule, Without Modifications
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga